Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
Carbonic anhydrase IX (CAIX, gene G250/MN-encoded transmembrane protein) is highly expressed in various human epithelial tumors such as renal clear cell carcinoma (RCC), but absent from the corresponding normal tissues. Besides the CA signal transduction activity, CAIX may serve as a biomarker in early stages of oncogenesis and also as a reliable marker of hypoxia, which is associated with tumor resistance to chemotherapy and radiotherapy. Although results from preclinical and clinical studies have shown CAIX as a promising target for detection and therapy for RCC, only a limited number of murine monoclonal antibodies (mAbs) and one humanized mAb are available for clinical testing and development. In this study, paramagnetic proteoliposomes of CAIX (CAIX-PMPLs) were constructed and used for anti-CAIX antibody selection from our 27 billion human single-chain antibody (scFv) phage display libraries. A panel of thirteen human scFvs that specifically recognize CAIX expressed on cell surface was identified, epitope mapped primarily to the CA domain, and affinity-binding constants (KD) determined. These human anti-CAIX mAbs are diverse in their functions including induction of surface CAIX internalization into endosomes and inhibition of the carbonic anhydrase activity, the latter being a unique feature that has not been previously reported for anti-CAIX antibodies. These human anti-CAIX antibodies are important reagents for development of new immunotherapies and diagnostic tools for RCC treatment as well as extending our knowledge on the basic structure-function relationships of the CAIX molecule.
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America.
Chen
C
Xu
Agnes
A
Lo
Anuradha
A
Yammanuru
Aimee St Clair
AS
Tallarico
Kristen
K
Brady
Akikazu
A
Murakami
Natasha
N
Barteneva
Quan
Q
Zhu
Wayne A
WA
Marasco
D000911:Antibodies, Monoclonal / Q000737:chemistry*; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism*; D014408:Biomarkers, Tumor; D019921:Biotinylation; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000276:immunology* / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000378:metabolism; D020134:Catalytic Domain; D011992:Endosomes / Q000378:metabolism; D018604:Epitope Mapping / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007680:Kidney Neoplasms / Q000378:metabolism; D007700:Kinetics; D019151:Peptide Library; D015398:Signal Transduction; D020349:Surface Plasmon Resonance
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D019151:Peptide Library; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases